Tricuspid RegUrgitaTion Hamburg Cohort
The TRUTH study is observing people who have a condition called tricuspid regurgitation (TR). This is where a valve on the right side of the heart doesn't close properly, letting blood leak backwards. This condition can be serious, and currently, surgery is the main treatment. However, surgery for this specific valve can be risky. New, less invasive treatments are being developed, but the unique shape of the tricuspid valve makes treatment complicated. This study wants to learn more about TR in real-world patients, regardless of what caused it or how it's being treated. By collecting information on many patients over time, researchers hope to improve how doctors predict who will benefit most from different treatments like medication, surgery, or new procedures.
At a glance
What is this study about?
The TRUTH study is focused on a heart condition called tricuspid regurgitation, or TR. This happens when the tricuspid valve, located on the right side of your heart, doesn't close tightly. This allows blood to flow backward, which can make your heart work harder and lead to serious health problems. Often, TR occurs because of other heart conditions, high blood pressure in the lungs, or an irregular heartbeat (atrial fibrillation).
Currently, surgery is the main treatment for TR, but operating on this particular valve can come with significant risks and poor results for some patients. Because of these challenges, doctors are looking into newer, less invasive procedures that involve using catheters (thin, flexible tubes) rather than open heart surgery. However, the tricuspid valve's complex shape and location make these new procedures difficult to get right.
This study aims to collect detailed information from a large group of patients with TR in Hamburg, Germany. By carefully watching how their condition develops and how they respond to different treatments – whether it's medication, surgery, or these newer procedures – the researchers hope to better understand TR. This knowledge will help doctors predict which treatments are most likely to work best for individual patients, leading to improved care and better outcomes for everyone with this condition.
Key takeaways
- The study focuses on understanding leaky heart valves (tricuspid regurgitation).
- It aims to improve how doctors treat this condition and predict who benefits most.
- Participation involves sharing medical information from your routine care.
- You won't receive new treatments or extra tests because of the study.
- Your involvement helps advance heart care for future patients.
Who may be eligible?
To be part of this study, you must be at least 18 years old and have a significant leaky tricuspid heart valve (doctors call this 'clinically relevant tricuspid regurgitation,' meaning it's at least a Grade III out of V in severity).
It's also important that you can understand and sign a consent form, which explains the study in detail. This means you need to be able to understand German well enough to read the study documents and participate in discussions without needing someone to translate for you.
Finally, you need to be physically and mentally capable of cooperating with the study requirements. If you're unable to do so, you wouldn't be able to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a significant leaky tricuspid heart valve (clinically relevant TR)?
- Can you understand spoken and written German well enough to participate?
- Are you able to agree to the study by signing a consent form and cooperate as needed?
What does participation involve?
This study is an observational study, meaning researchers will monitor your condition and treatment as part of your usual medical care. You won't be given any new medications or treatments specifically for the study. Instead, they will collect information from your regular doctor's appointments and tests. The study will track your health over time, but the exact number of visits or total duration isn't specified, as it's based on your ongoing clinical routine. You simply need to consent for your medical information related to TR to be collected and analysed.
Potential risks and benefits
Locations (1)
- University Heart and Vascular Center HamburgVerified postcodeHamburg, Germany· Recruiting
Common questions
What is tricuspid regurgitation?
It's a heart condition where a valve on the right side of your heart (the tricuspid valve) doesn't close properly, causing blood to leak backward.
Why is this study important?
It helps doctors understand the condition better and find out which treatments work best for different patients, leading to improved care in the future.
Will I have to take new medicine or get extra tests for this study?
No, this study only observes your condition and treatment as part of your regular medical care. No new medicines or extra tests are given specifically for the study.
Can I leave the study if I change my mind?
Yes, you can decide to leave the study at any time, and it will not affect the medical care you receive.
Is this study only for people in Hamburg, Germany?
Yes, this specific study is collecting information from patients in Hamburg, Germany, to monitor their 'real-world' care.
How to find out more
Benedikt Koell, MD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.